Systemic sclerosis & Raynaud's

Type II diabetes in systemic sclerosis patients: insights from an observational, multicenter study of GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale)

Arthritis Res TherPublished Cross-sectional study

Authors' conclusion

Although the prevalence of T2D in SSc patients is lower than the global estimates reported by the International Federation of Diabetes (IFD), a distinct subgroup of SSc patients with T2D is characterized by unique disease manifestations and complications, including SRC and impaired lung function.

Study context

Population
Systemic sclerosis (SSc) patients from 11 tertiary Rheumatology Units across Italy
Participants
613 patients11 centres
Exposure
SSc patients with T2D vs without T2D
Outcome
Prevalence of T2D and SSc-specific factors associated with T2D
Methodological detailsobservational, multicentre
  • Observational
  • Multicentre

Main finding

As reported in the abstract

Prevalence of T2D

Prevalence of T2D in the cohort

7.6%

Observational data: associations, not effects.

Further findings

Features of SSc with T2D vs non-T2D (univariate)

Older age in T2D
P < 0.007
Higher prevalence of late-stage capillaroscopic pattern
P < 0.001
Severe FVC reduction (FVC < 50%)
P < 0.000
Moderate TLC reduction (TLC 50-69%)
P < 0.011
ECG signs of right ventricular hypertrophy
P < 0.018
Higher prevalence of PAH confirmed by right heart catheterization (RHC)
P < 0.037
Higher prevalence of scleroderma renal crisis (SRC)
P < 0.001
Elevated erythrocyte sedimentation rate (ESR)
P < 0.022
More frequent angiotensin-converting enzyme inhibitors (ACEi) use
P < 0.005
ANA positivity
Use of immunosuppressive therapies similar between groups

Original publication

Type II diabetes in systemic sclerosis patients: insights from an observational, multicenter study of GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale). Arthritis Res Ther. Published 28 July 2025. doi:10.1186/s13075-025-03619-3

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.